In mice with progressive liver metastatic disease, blockade of TGF-β signaling improves the susceptibility to anti-PD-1 therapy and suggests that TGF-β inhibition could prevent, but not reverse, CAF differentiation (186). This evidence concerns the gene TGFB1 and metastatic neoplasm.